MX2020007941A - Metodo para prevenir o tratar enfermedad de alzheimer. - Google Patents
Metodo para prevenir o tratar enfermedad de alzheimer.Info
- Publication number
- MX2020007941A MX2020007941A MX2020007941A MX2020007941A MX2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- preventing
- treating alzheimer
- subject
- dapansutrile
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- LQFRYKBDZNPJSW-UHFFFAOYSA-N 3-methylsulfonylpropanenitrile Chemical compound CS(=O)(=O)CCC#N LQFRYKBDZNPJSW-UHFFFAOYSA-N 0.000 abstract 2
- 229950002291 dapansutrile Drugs 0.000 abstract 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624637P | 2018-01-31 | 2018-01-31 | |
| PCT/US2019/016012 WO2019152627A1 (en) | 2018-01-31 | 2019-01-31 | Method for preventing or treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007941A true MX2020007941A (es) | 2020-09-03 |
Family
ID=67478566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007941A MX2020007941A (es) | 2018-01-31 | 2019-01-31 | Metodo para prevenir o tratar enfermedad de alzheimer. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11517554B2 (https=) |
| EP (1) | EP3746057B1 (https=) |
| JP (1) | JP7290872B2 (https=) |
| CN (1) | CN111670032A (https=) |
| CA (1) | CA3087865A1 (https=) |
| MX (1) | MX2020007941A (https=) |
| WO (1) | WO2019152627A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7229565B2 (ja) * | 2018-03-21 | 2023-02-28 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | メラノーマを治療するための方法 |
| EP4045009A4 (en) * | 2019-10-14 | 2023-11-01 | Olatec Therapeutics LLC | METHOD FOR TREATING BREAST CANCER |
| CN117897151A (zh) * | 2021-08-19 | 2024-04-16 | 欧拉泰克治疗公司 | 用于治疗帕金森氏病的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651407B1 (en) * | 2010-12-15 | 2016-12-21 | Olatec Industries LLC | 3-methanesulfonylpropionitrile for treating inflammation and pain |
| EP3563849A3 (en) * | 2012-10-25 | 2020-02-12 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| WO2014194166A1 (en) * | 2013-05-31 | 2014-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat alzheimer's disease |
| WO2015165961A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| WO2016138425A1 (en) * | 2015-02-26 | 2016-09-01 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
-
2019
- 2019-01-31 CA CA3087865A patent/CA3087865A1/en active Pending
- 2019-01-31 JP JP2020541528A patent/JP7290872B2/ja active Active
- 2019-01-31 MX MX2020007941A patent/MX2020007941A/es unknown
- 2019-01-31 WO PCT/US2019/016012 patent/WO2019152627A1/en not_active Ceased
- 2019-01-31 CN CN201980011347.7A patent/CN111670032A/zh active Pending
- 2019-01-31 EP EP19746676.6A patent/EP3746057B1/en active Active
-
2020
- 2020-07-29 US US16/942,312 patent/US11517554B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021512086A (ja) | 2021-05-13 |
| WO2019152627A1 (en) | 2019-08-08 |
| CA3087865A1 (en) | 2019-08-08 |
| EP3746057A1 (en) | 2020-12-09 |
| EP3746057B1 (en) | 2024-03-20 |
| EP3746057A4 (en) | 2021-10-13 |
| CN111670032A (zh) | 2020-09-15 |
| JP7290872B2 (ja) | 2023-06-14 |
| US20200352897A1 (en) | 2020-11-12 |
| US11517554B2 (en) | 2022-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001299A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| PH12021500006A1 (en) | Methods of treatment and prevention of alzheimer's disease | |
| MX2023007998A (es) | Regimenes de tratamiento con dexmedetomidina. | |
| MX2022010748A (es) | Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1). | |
| MX2020007941A (es) | Metodo para prevenir o tratar enfermedad de alzheimer. | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| MX2024000701A (es) | Metodos de tratamiento de la enfermedad de alzheimer. | |
| BR112023017999A2 (pt) | Obicetrapibe para tratamento de demências | |
| MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
| FR3079141B1 (fr) | Utilisations de derives de curcumine | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| JP2021512086A5 (https=) | ||
| EA202192928A1 (ru) | Терапевтическое лекарственное средство для лечения дискинезии | |
| EA202190406A1 (ru) | Способы лечения нейродегенеративных расстройств | |
| MX2024007043A (es) | Purinas y métodos de uso. | |
| MX2024005084A (es) | Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada. | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |